Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination

References

• World Health Organization Western Pacific Region. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Manila: World Health Organization Western Pacific Region; [accessed 2019 Apr 10]. https://iris.wpro.who.int/bitstream/handle/10665.1/5521/9789290615255_eng.pdf.
   Google Scholar
• Chinese center for disease control and prevention. National notifiable disease reported system (HFMD) from 2008 to 2017. http://www.chinacdc.cn/jkzt/crb/bl/szkb/cbw_2274/. Accessed 10 April 2019.
   Google Scholar
• Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998–2005. Pediatrics. 2007;120:e244–52. doi:10.1542/peds.2006-3331.
   PubMed Web of Science ®Google Scholar
• Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang J-R, Shih S-R. An epidemic of enterovirus 71 infection in Taiwan. Taiwan enterovirus epidemic working group. N Engl J Med. 1999;341:929–35. doi:10.1056/NEJM199909233411301.
   PubMed Web of Science ®Google Scholar
• Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, Hsueh C, Shih S-R, Liu -C-C, Wu M-H. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis. 2002;34(Suppl 2):S52–7. doi:10.1086/338819.
   PubMedGoogle Scholar
• Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis. 2003;9:291–93. doi:10.3201/eid0903.020285.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–32. doi:10.1016/S0140-6736(13)61049-1.
   PubMed Web of Science ®Google Scholar
• Ooi MH, Wong SC, Mohan A, Podin Y, Perera D, Clear D, Del Sel S, Chieng CH, Tio PH, Cardosa MJ, et al. Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis. 2009;9:3. doi:10.1186/1471-2334-9-3.
   PubMed Web of Science ®Google Scholar
• Ooi MH, Wong SC, Podin Y, Akin W, Del Sel S, Mohan A, Chieng C, Perera D, Clear D, Wong D, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44:646–56. doi:10.1086/522508.
   PubMed Web of Science ®Google Scholar
• An ZJ, Liu Y, Liao QH, et al. Guidelines for use of inactivated enterovirus type 71 vaccine. Chin J Vacc Immun. 2016;6(4):458–64.
   Google Scholar
• China Food and Drug Administration. The standard guidelines for adverse reactions grading of vaccine clinical trials. [accessed 2019 Apr 10]. http://wwwsdagovcn/WS01/CL0844/9350_5html.
   Google Scholar
• Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829–37. doi:10.1056/NEJMoa1303224.
   PubMed Web of Science ®Google Scholar
• Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–28. doi:10.1056/NEJMoa1304923.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zeng G, Chu K, Zhang J, Han W, Zhang Y, Li J, Zhu F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation. Hum Vaccin Immunother. 2018;14:1517–23. doi:10.1080/21645515.2018.1442997.
   PubMed Web of Science ®Google Scholar
• Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, Xia JL, Li J, Zhu FC. Two-year efficacy and immunogenicity of Sinovac enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016;15:129–37. doi:10.1586/14760584.2016.1096782.
   PubMed Web of Science ®Google Scholar
• Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, Hu Y, Liu P, Shi N, Tao H, et al. 2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy chinese children: a randomized open-label study. J Infect Dis. 2017;215:56–63. doi:10.1093/infdis/jiw502.
   PubMed Web of Science ®Google Scholar
• Jin P, Li J, Zhang X, Meng F, Zhou Y, Yao X, Gan Z, Zhu F. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6–35 months. Hum Vaccin Immunother. 2016;12:916–21. doi:10.1080/21645515.2015.1118595.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liang Z, Zeng J, Zhang J, He P, Su J, Zeng Y, Fan R, Zhao D, Ma W, et al. Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis B vaccine and group A meningococcal polysaccharide vaccine: a phase 4, open-label, single-center, randomized, noninferiority trial. J Infect Dis. 2019;220:392–99. doi:10.1093/infdis/jiz129.
   PubMed Web of Science ®Google Scholar
• Mao Q, Cheng T, Zhu F, Li J, Wang Y, Li Y, Gao F, Yang L, Yao X, Shao J, et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children. PLoS One. 2013;8:e79599. doi:10.1371/journal.pone.0079599.
   PubMed Web of Science ®Google Scholar
• Ren YH, Chen JT, Wu WT. Evaluation on different immunization schedules of hepatitis A vaccine healive. Chin J Vaccines Immun. 2003;9:219–21.
   Google Scholar
• Wang DM, Shi ZH, Zhu HM. The observation of antibody dynamic in children who inactivated hepatitis A vaccine Chinese. J Vaccines Immunization. 2010;16(1):4–4.
   Google Scholar
• Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao Q-Y, Wen S-Q, Huang R-G, Hu Y-S, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2014;209:46–55. doi:10.1093/infdis/jit429.
   PubMed Web of Science ®Google Scholar
• National Health Commission of People’s Republic of China. The guidelines for the diagnosis and treatment of hand foot and mouth disease; 2018. edition.
   Google Scholar
• MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM, Zuniga E, Cook MC, Vinuesa CG. Extrafollicular antibody responses. Immunol Rev. 2003;194:8–18. doi:10.1034/j.1600-065X.2003.00058.x.
   PubMed Web of Science ®Google Scholar